Data availability
No data are available for this manuscript. Medical reports for this case are available upon reasonable request.
Change history
27 December 2023
A Correction to this paper has been published: https://doi.org/10.1007/s00277-023-05599-3
References
Feng J, Pucella JN, Jang G et al (2022) Clonal lineage tracing reveals shared origin of conventional and plasmacytoid dendritic cells. Immunity 55(3):405-422.e11. https://doi.org/10.1016/j.immuni.2022.01.016
Cella M, Jarrossay D, Facchetti F, Alebardi O, Nakajima H, Lanzavecchia A, Colonna M (1999) Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med 5(8):919–23. https://doi.org/10.1038/11360
El Hussein S, Wang W (2023) Plasmacytoid dendritic cells in the setting of myeloid neoplasms: diagnostic guide to challenging pathologic presentations. Br J Haematol Published online. https://doi.org/10.1111/bjh.18632
Arber DA, Orazi A, Hasserjian RP et al (2022) International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 140(11):1200–1228. https://doi.org/10.1182/blood.2022015850
Khoury JD, Solary E, Abla O et al (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 36(7):1703–1719. https://doi.org/10.1038/s41375-022-01613-1
Gong X, Li C, Wang Y et al (2022) Mature plasmacytoid dendritic cells associated with acute myeloid leukemia show similar genetic mutations and expression profiles to leukemia cells. Blood Science 4(1):38–43. https://doi.org/10.1097/BS9.0000000000000097
Zalmaï L, Viailly PJ, Biichle S et al (2020) Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape. Haematologica 106(12):3056–3066. https://doi.org/10.3324/haematol.2020.253740
Brunetti L, di Battista V, Venanzi A et al (2017) Blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia: a shared clonal origin. Leukemia 31(5):1238–1240. https://doi.org/10.1038/leu.2017.38
Author information
Authors and Affiliations
Contributions
G.C. and G.M. collected the data and wrote the manuscript; M.C., G.P., V.C., S.S., and M.Q. contributed to the clinical management of the patient and discussion of data; E.T, A.V. and C.Ma. performed NGS analysis on bone marrow and skin samples. C.Ma. performed NGS analysis; S.A., C.Me., and M.P.M. coordinated the work, reviewed data, and wrote the manuscript. All authors reviewed and approved the final version of the manuscript.
Corresponding authors
Ethics declarations
Ethics approval
N/A.
Patient consent
Patient’s written consent to the publication of this case has been obtained.
Conflict of interest
MPM declares honoraria from Rasna Therapeutics, Inc. for scientific advisor activities and honoraria/consultancy at scientific advisory board for Abbvie, Amgen, Celgene, Janssen, Novartis, Pfizer, and Jazz Pharmaceuticals. The other authors have no COI to disclose. ET and AV, as the other authors, have no COI to disclose.
Permission to reproduce material from other sources
N/A.
Clinical trial registration
N/A.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Giovanni Martino and Gaetano Cimino are co-first contributors.
Stefano Ascani, Cristina Mecucci, and Maria Paola Martelli are co-last contributors.
The original version of this article was revised: This article was originally published with incomplete authors Prof. Enrico Tiacci and Dr. Alessandra Venanzi.
Rights and permissions
About this article
Cite this article
Martino, G., Cimino, G., Caridi, M. et al. One disease, two faces: clonally-related AML and MPDCP with skin involvement. Ann Hematol 102, 2969–2971 (2023). https://doi.org/10.1007/s00277-023-05377-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-023-05377-1